LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article ; Online: Características de los pacientes con infección por el virus de la inmunodeficiencia humana que no reciben tratamiento antirretroviral en España: estudio PICNIT.

Domingo Pedrol, Pere / Viciana Fernández, Pompeyo / Castaño, Manuel / Ferrer Corbera, Elena

2015 Volume 144, Issue 1, Page(s) 43–44

Title translation	Characteristics of human immunodeficiency virus-infected patients without antiretroviral treatment in Spain: PICNIT study.
MeSH term(s)	Adult ; Cross-Sectional Studies ; Female ; HIV Infections/drug therapy ; Health Surveys/statistics & numerical data ; Hospital Units/statistics & numerical data ; Humans ; Male ; Risk Factors ; Socioeconomic Factors ; Spain/epidemiology
Language	Spanish
Publishing date	2015-01-06
Publishing country	Spain
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1016/j.medcli.2014.01.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells.

Garreta, Elena / Prado, Patricia / Stanifer, Megan L / Monteil, Vanessa / Marco, Andrés / Ullate-Agote, Asier / Moya-Rull, Daniel / Vilas-Zornoza, Amaia / Tarantino, Carolina / Romero, Juan Pablo / Jonsson, Gustav / Oria, Roger / Leopoldi, Alexandra / Hagelkruys, Astrid / Gallo, Maria / González, Federico / Domingo-Pedrol, Pere / Gavaldà, Aleix / Del Pozo, Carmen Hurtado /

Hasan Ali, Omar / Ventura-Aguiar, Pedro / Campistol, Josep María / Prosper, Felipe / Mirazimi, Ali / Boulant, Steeve / Penninger, Josef M / Montserrat, Nuria

Cell metabolism

2022 Volume 34, Issue 6, Page(s) 857–873.e9

Abstract: It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. Upon SARS-CoV-2 infection, diabetic- ...

Abstract	It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. Upon SARS-CoV-2 infection, diabetic-like kidney organoids exhibited higher viral loads compared with their control counterparts. Genetic deletion of the angiotensin-converting enzyme 2 (ACE2) in kidney organoids under control or diabetic-like conditions prevented viral detection. Moreover, cells isolated from kidney biopsies from diabetic patients exhibited altered mitochondrial respiration and enhanced glycolysis, resulting in higher SARS-CoV-2 infections compared with non-diabetic cells. Conversely, the exposure of patient cells to dichloroacetate (DCA), an inhibitor of aerobic glycolysis, resulted in reduced SARS-CoV-2 infections. Our results provide insights into the identification of diabetic-induced metabolic programming in the kidney as a critical event increasing SARS-CoV-2 infection susceptibility, opening the door to the identification of new interventions in COVID-19 pathogenesis targeting energy metabolism.
MeSH term(s)	Angiotensin-Converting Enzyme 2/metabolism ; COVID-19 ; Diabetes Mellitus ; Diabetic Nephropathies ; Humans ; Kidney/metabolism ; Organoids ; Peptidyl-Dipeptidase A/genetics ; Peptidyl-Dipeptidase A/metabolism ; SARS-CoV-2
Chemical Substances	Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
Language	English
Publishing date	2022-05-12
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2176834-1
ISSN	1932-7420 ; 1550-4131
ISSN (online)	1932-7420
ISSN	1550-4131
DOI	10.1016/j.cmet.2022.04.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6169: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Análisis comparativo de coste-eficacia entre darunavir/ritonavir y otros inhibidores de la proteasa en el tratamiento de la infección por el virus de la inmunodeficiencia humana de tipo 1 en pacientes naïve en España.

Smets, Erik / Brogan, Anita J / Hill, Andrew / Adriaenssen, Ines / Sawyer, Anthony W / Domingo-Pedrol, Pere / Gostkorzewicz, Joana / Ledesma, Francisco

Enfermedades infecciosas y microbiologia clinica

2013 Volume 31, Issue 7, Page(s) 430–436

Abstract: Introduction: GESIDA (AIDS Study Group) has proposed preferred regimens of antiretroviral treatment as initial therapy in HIV infected patients. The objective of this analysis is to compare the costs and effectiveness of darunavir/r QD and other ... ...

Title translation	Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain.
Abstract	Introduction: GESIDA (AIDS Study Group) has proposed preferred regimens of antiretroviral treatment as initial therapy in HIV infected patients. The objective of this analysis is to compare the costs and effectiveness of darunavir/r QD and other ritonavir-boosted (/r) protease inhibitors (PIs) currently recommended in GESIDA guidelines for treatment-naïve patients. Methods: A cost-efficacy model compared the boosted PIs recommended as preferred or alternative treatment choices, each used with a nucleoside reverse transcriptase inhibitor backbone. Efficacy was measured by 48-week virological response (viral load < 50 copies/mL) adjusted by baseline viral load and CD4 cell count. To generate efficiency frontiers and cost-efficacy ratios, one-year antiretroviral therapy costs in Spain, and 48-week efficacy values were used. Results: The model estimated that starting treatment with darunavir/r QD was the most cost-effective choice compared with the other preferred PI/r based therapies. The average cost per patient with a virological response was lower for darunavir/r QD (13,420€) than for atazanavir/r QD (14,000€), or lopinavir/r BID (13,815€). Among the preferred PI/r-based therapies, darunavir/r QD also was estimated to be the most efficient option for treatment-naïve patients. Atazanavir/r QD and lopinavir/r BID were found to be «dominated» by darunavir/r) and, consequently, were outside the efficiency frontier of PI/r-based first-line treatment. Given a fixed budget of 10 million euros for PI/r-based first-line therapy, the model estimated that darunavir/r QD would yield more responders (745) than atazanavir/r QD (714), or lopinavir/r BID (724). At the same time, darunavir/r QD would reduce the number of individuals failing treatment (150) compared with atazanavir/r QD (172) and lopinavir/r BID (286). Conclusions: In this model, darunavir/r QD was found to be the most cost-effective choice, among the preferred PI/r-based therapies recommended in the Spanish guidelines for treatment-naïve patients.
MeSH term(s)	Adult ; Atazanavir Sulfate ; Cost-Benefit Analysis ; Darunavir ; Female ; HIV Protease Inhibitors/economics ; HIV Protease Inhibitors/therapeutic use ; HIV-1 ; Humans ; Lopinavir/economics ; Lopinavir/therapeutic use ; Male ; Oligopeptides/economics ; Oligopeptides/therapeutic use ; Pyridines/economics ; Pyridines/therapeutic use ; Ritonavir/economics ; Ritonavir/therapeutic use ; Spain ; Sulfonamides/economics ; Sulfonamides/therapeutic use
Chemical Substances	HIV Protease Inhibitors ; Oligopeptides ; Pyridines ; Sulfonamides ; Lopinavir (2494G1JF75) ; Atazanavir Sulfate (4MT4VIE29P) ; Ritonavir (O3J8G9O825) ; Darunavir (YO603Y8113)
Language	Spanish
Publishing date	2013-08
Publishing country	Spain
Document type	Comparative Study ; English Abstract ; Journal Article
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/j.eimc.2012.11.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Toxicogenética del tratamiento antirretroviral (I): lipodistrofia, alteraciones metabólicas y arteriosclerosis.

Gutiérrez Maciá, M Mar / Mateo García, M Gracia / Vidal Marsal, Francesc / Domingo Pedrol, Pere

Enfermedades infecciosas y microbiologia clinica

2008 Volume 26 Suppl 6, Page(s) 18–23

Abstract: Among the adverse effects attributed to antiretroviral therapy, one of the most striking is probably the appearance of the lipodystrophy syndrome and its associated metabolic derangements, given its potential long-term effect as a cardiovascular risk ... ...

Title translation	Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis.
Abstract	Among the adverse effects attributed to antiretroviral therapy, one of the most striking is probably the appearance of the lipodystrophy syndrome and its associated metabolic derangements, given its potential long-term effect as a cardiovascular risk factor. Since not all patients who receive antiretroviral drugs experience these adverse effects, a host genetic predisposition has been postulated. However, currently available data on this issue is inconclusive and preliminary. It has been consistently demonstrated that polymorphisms in the genes that encode for apolipoproteins A5, C3 and E, for the cholesterol ester transporter proteins (CETP), and in the ATP binding cassette type A1 (ABCA1) influence the development of dyslipidemia in patients treated with antiretroviral drugs, particularly if the therapeutic regimen includes protease inhibitors. Data on the effect of polymorphisms in the sterol regulatory ester binding protein type 1 (SREBP1) are inconsistent. The effect of mitochondrial DNA mutations on the risk of lipodystrophy has been assessed, with inconclusive data. No polymorphisms in the lamin A gene have been detected. Investigations have assessed the effect of diverse polymorphisms in the genes that encode for several proinflammatory cytokines such as tumour necrosis factor alpha (TNF-alpha), interleukin-1-beta (IL-1beta) and interleukin-6 (IL-6). The results show inconsistent data in the case of TNF-alpha, no association in the case of IL-6, and preliminary positive associations in IL-1beta. In contrast, polymorphisms in the genes encoding for stromal derived factor 1 (SDF-1) and for monocyte chemoattractant protein 1 (MCP-1) have been shown to influence the development of subclinical atherosclerosis in HIV-1-infected patients treated with antiretroviral drugs.
MeSH term(s)	Anti-Retroviral Agents/adverse effects ; Atherosclerosis/chemically induced ; Atherosclerosis/genetics ; HIV Infections/drug therapy ; HIV-1 ; HIV-Associated Lipodystrophy Syndrome/chemically induced ; HIV-Associated Lipodystrophy Syndrome/genetics ; Humans ; Metabolic Diseases/chemically induced ; Metabolic Diseases/genetics ; Polymorphism, Genetic ; Toxicogenetics
Chemical Substances	Anti-Retroviral Agents
Language	Spanish
Publishing date	2008-05-23
Publishing country	Spain
Document type	English Abstract ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/s0213-005x(08)76508-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana.

Martínez, Esteban / Jódar Gimeno, Esteban / Reyes García, Rebeca / Carpintero, Pedro / Casado, José Luis / Del Pino Montes, Javier / Domingo Pedrol, Pere / Estrada, Vicente / Maalouf, Jorge / Negredo, Eugenia / Ocampo, Antonio / Muñoz-Torres, Manuel

Enfermedades infecciosas y microbiologia clinica

2014 Volume 32, Issue 4, Page(s) 250–258

Abstract: Objective: To provide practical recommendations for the evaluation and treatment of metabolic bone disease in human immunodeficiency virus (HIV) patients.: Participants: Members of scientific societies related to bone metabolism and HIV: Grupo de ... ...

Title translation	Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients.
Abstract	Objective: To provide practical recommendations for the evaluation and treatment of metabolic bone disease in human immunodeficiency virus (HIV) patients. Participants: Members of scientific societies related to bone metabolism and HIV: Grupo de Estudio de Sida (GeSIDA), Sociedad Española de Endocrinología y Nutrición (SEEN), Sociedad Española de Investigación Ósea y del Metabolismo Mineral (SEIOMM), and Sociedad Española de Fractura Osteoporótica (SEFRAOS). Methods: A systematic search was carried out in PubMed, and papers in English and Spanish with a publication date before 28 May 2013 were included. Recommendations were formulated according to GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) setting both their strength and the quality of supporting evidence. Working groups were established for each major part, and the final resulting document was later discussed in a face-to-face meeting. All the authors reviewed the final written document and agreed with its content. Conclusions: The document provides evidence-based practical recommendations on the detection and treatment of bone disease in HIV-infected patients.
MeSH term(s)	Algorithms ; Bone Diseases, Metabolic/complications ; Bone Diseases, Metabolic/diagnosis ; Bone Diseases, Metabolic/therapy ; HIV Infections/complications ; Humans ; Osteoporosis/complications ; Osteoporosis/diagnosis ; Osteoporosis/therapy
Language	Spanish
Publishing date	2014-04
Publishing country	Spain
Document type	Consensus Development Conference ; English Abstract ; Journal Article ; Practice Guideline
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/j.eimc.2013.07.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A diabetic milieu increases cellular susceptibility to SARS-CoV-2 infections in engineered human kidney organoids and diabetic patients

Garreta, Elena / Prado, Patricia / Stanifer, Megan / Monteil, Vanessa / del Pozo, Carmen Hurtado / Ullate-Agote, Asier / Vilas-Zornoza, Amaia / Romero, Juan Pablo / Jonsson, Gustav / Oria, Roger / Leopoldi, Alexandra / Hagelkruys, Astrid / Moya-Rull, Daniel / González, Federico / Marco, Andrés / Tarantino, Carolina / Domingo-Pedrol, Pere / HasanAli, Omar / Ventura-Aguiar, Pedro /

María Campistol, Josep / Prosper, Felipe / Mirazimi, Ali / Boulant, Steeve / Penninger, Josef M. / Montserrat, Nuria

bioRxiv

Abstract: SARS-CoV-2 infections lead to a high risk of hospitalization and mortality in diabetic patients. Why diabetic individuals are more prone to develop severe COVID-19 remains unclear. Here, we established a novel human kidney organoid model that mimics ... ...

Abstract	SARS-CoV-2 infections lead to a high risk of hospitalization and mortality in diabetic patients. Why diabetic individuals are more prone to develop severe COVID-19 remains unclear. Here, we established a novel human kidney organoid model that mimics early hallmarks of diabetic nephropathy. High oscillatory glucose exposure resulted in metabolic changes, expansion of extracellular membrane components, gene expression changes determined by scRNAseq, and marked upregulation of angiotensin-converting enzyme 2 (ACE2). Upon SARS-CoV-2 infection, hyperglycemic conditions lead to markedly higher viral loads in kidney organoids compared to normoglycemia. Genetic deletion of ACE2, but not of the candidate receptor BSG/CD147, in kidney organoids demonstrated the essential role of ACE2 in SARS-CoV-2 infections and completely prevented SARS-CoV-2 infection in the diabetogenic microenvironment. These data introduce a novel organoid model for diabetic kidney disease and show that diabetic-induced ACE2 licenses the diabetic kidney to enhanced SARS-CoV-2 replication.
Keywords	covid19
Language	English
Publishing date	2021-08-13
Publisher	Cold Spring Harbor Laboratory
Document type	Article ; Online
DOI	10.1101/2021.08.13.456228
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A diabetic milieu increases cellular susceptibility to SARS-CoV-2 infections in engineered human kidney organoids and diabetic patients

Garreta, Elena / Prado, Praticia / Stanifer, Megan L. / Monteil, Vanessa / Hurtado del Pozo, Carmen / Ullate-Agote, Asier / Vilas-Zornoza, Amaia / Romero, Juan Pablo / Jonsson, Gustav / Oria, Roger / Leopoldi, Alexandra / Hagelkrueys, Astrid / Moya-Rull, Daniel / Gonzalez, Federico / Marco, Andres / Tarantino, Carolina / Domingo-Pedrol, Pere / HasanAli, Omar / Ventura-Aguiar, Pedro /

Campistol, Josep Maria / Prosper, Felipe / Mirazimi, Ali / Boulant, Steeve / Penninger, Josef / Montserrat, Nuria

bioRxiv

Abstract	SARS-CoV-2 infections lead to a high risk of hospitalization and mortality in diabetic patients. Why diabetic individuals are more prone to develop severe COVID-19 remains unclear. Here, we established a novel human kidney organoid model that mimics early hallmarks of diabetic nephropathy. High oscillatory glucose exposure resulted in metabolic changes, expansion of extracellular membrane components, gene expression changes determined by scRNAseq, and marked upregulation of angiotensin-converting enzyme 2 (ACE2). Upon SARS-CoV-2 infection, hyperglycemic conditions lead to markedly higher viral loads in kidney organoids compared to normoglycemia. Genetic deletion of ACE2, but not of the candidate receptor BSG/CD147, in kidney organoids demonstrated the essential role of ACE2 in SARS-CoV-2 infections and completely prevented SARS-CoV-2 infection in the diabetogenic microenvironment. These data introduce a novel organoid model for diabetic kidney disease and show that diabetic-induced ACE2 licenses the diabetic kidney to enhanced SARS-CoV-2 replication.
Keywords	covid19
Language	English
Publishing date	2021-08-13
Publisher	Cold Spring Harbor Laboratory
Document type	Article ; Online
DOI	10.1101/2021.08.13.456228
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Prevalencia de hipertensión arterial y perfil lipídico en pacientes con infección por el virus de la inmunodeficiencia humana.

Coloma Conde, Ana G / Alvarez Albarrán, Maite / Roca-Cusachs Coll, Alejandro / Domingo Pedrol, Pere / Puig Campmany, Mireia

Medicina clinica

2008 Volume 131, Issue 18, Page(s) 681–684

Abstract: Background and objective: It is not known whether human immunodeficiency virus (HIV)-infected patients present, compared to non-HIV controls, higher vascular risk factors. Our objective was to analyze whether there are differences in blood pressure in ... ...

Title translation	Prevalence of arterial hypertension and lipid profile in HIV patients.
Abstract	Background and objective: It is not known whether human immunodeficiency virus (HIV)-infected patients present, compared to non-HIV controls, higher vascular risk factors. Our objective was to analyze whether there are differences in blood pressure in HIV patients compared to non-HIV controls. Patients and method: We retrospectively analyzed all HIV patients controlled in our centre, who were compared with a control group of blood donors, matched for age and sex, blood pressure and lipid profile. We evaluated the following variables: demographic data, date of HIV diagnosis, presence of lipodystrophy, antiretroviral treatment, duration of this treatment, and vascular risk factors. Results: We evaluated 740 patients (mean age: 41.8 years; 75% men). We detected a higher prevalence of hypertension in the HIV group (25% vs. 15%) with a significant difference in the mean systolic/diastolic blood pressure between both groups (p < 0.0001). In the HIV group, hypertensives were older than normotensives, and had higher prevalence of lipodystrophy and higher total cholesterol with a shorter disease duration (75 vs 85 months). In the total group of hypertensives, HIV patients were younger than non-HIV (44.2 vs 47.9 years; p < 0.009) and had higher total cholesterol values (5.44 vs 5.18 mmol/l; p < 0.052). Conclusions: We found a higher prevalence of hypertension in HIV patients compared with matched controls, as well as a higher prevalence of lipodystrophy and vascular risk factors in hypertensive HIV patients compared with non-hypertensive.
MeSH term(s)	Adult ; Cholesterol/blood ; Cholesterol, HDL/blood ; Female ; HIV Infections/complications ; Humans ; Hypertension/blood ; Hypertension/complications ; Hypertension/epidemiology ; Male ; Prevalence ; Retrospective Studies
Chemical Substances	Cholesterol, HDL ; Cholesterol (97C5T2UQ7J)
Language	Spanish
Publishing date	2008-11-24
Publishing country	Spain
Document type	Comparative Study ; English Abstract ; Journal Article
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1157/13129111
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.

Carrero-Gras, Ana / Antela, Antonio / Muñoz-Rodríguez, Jessica / Díaz-Menéndez, Marta / Viciana, Pompeyo / Torrella-Domingo, Adriadna / Sanz-Moreno, José / Téllez-Molina, María Jesús / Moreno, Javier / Hernández-Quero, José / Pérez-Hernández, Isabel A / Domingo-Pedrol, Pere

Journal of the International AIDS Society

2014 Volume 17, Issue 4 Suppl 3, Page(s) 19819

Abstract: Background: The advent of combined antiretroviral therapy (ART) in the past decade has led to HIV suppression in most cases. Virological failure was the main reason for ART switch a few years ago; however, toxicity and treatment simplification have now ... ...

Abstract	Background: The advent of combined antiretroviral therapy (ART) in the past decade has led to HIV suppression in most cases. Virological failure was the main reason for ART switch a few years ago; however, toxicity and treatment simplification have now gained importance due to the availability of more effective and convenient drugs. This study assessed the reasons for ART switch in daily practice. Material and methods: Observational retrospective study that included patients whose ART was switched between January 2011 and July 2012. Patients with any other switch during the follow-up period (until September 2013) were excluded. Results: A total of 246 patients were included. Main reasons for ART switch were simplification (33%) and toxicity (31%), followed by clinical trial inclusion (13%), virological failure (6%), drug interaction (4%), patient decision (3%), lack of adherence (2%), pregnancy (1%) and other (8%). Eighty patients switched to a simpler regimen (median age 48 [40-53], mean CD4 count 608±265 cells/cl, 89% <50 copies/ml, mean number of previous regimens 6±5, mean time on previous ART 3±2 years). In this case, previous ART mostly included 2NRTI+1PI/r (54%) (Figure 1). The simplification strategy mainly contained nuke-sparing regimens (60%) based on PI (DRV/r 48%): monotherapy 46%, dual therapy 13% (PI/r+maraviroc 9%, PI/r+NNRTI 4%) and triple therapy 1% (PI/r+maraviroc+raltegravir). The second preferred simplification option was 2NRTI+1NNRTI (24%). Seventy-seven patients switched due to toxicities (median age 47 [43-53], mean CD4 count 606±350 cells/μl, <50 copies/ml 82%, mean number of previous regimens 4±3, mean time on previous ART 3±3 years). Renal (25%) and CNS (18%) toxicities were the main reasons for ART switch, followed by diarrhoea (16%), liver enzyme elevation (ALT 10%; AST 9%; bilirubin 7%), lipid elevation (cholesterol 5%; triglycerides 8%), nausea (7%) and other (=5%) (Figure 2). All patients with renal toxicity were under TDF and in most cases this drug was removed from the new regimen (with 3TC/ABC or nuke-sparing). Among patients with CNS toxicity, 79% were taking EFV; the main new treatment was a second-generation NNRTI (ETR)+2NRTI. Toxicities were completely resolved in 66% of patients, partially resolved in 22% and not resolved in only 12%; the median time from ART switch to toxicity resolution was 4 (2-8) months. Conclusions: The main reasons for ART switch in daily practice are simplification and toxicities, renal and CNS toxicities being the most prevalent. The preferred simplification strategies are nuke-sparing regimens, mainly DRV/r-based monotherapy and dual therapy. ART switch leads to a complete resolution of toxicities in most cases in the short term.
Language	English
Publishing date	2014
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2467110-1
ISSN	1758-2652 ; 1758-2652
ISSN (online)	1758-2652
ISSN	1758-2652
DOI	10.7448/IAS.17.4.19819
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Executive summary of the Consensus Statement on monitoring HIV: pregnancy, birth, and prevention of mother-to-child transmission.

Polo Rodríguez, Rosa / Muñoz Galligo, Eloy / Iribarren, José Antonio / Domingo Pedrol, Pere / Leyes García, María / Maiques Montesinos, Vicente / Miralles Martín, Pilar / Noguera Julian, Antoni / Ocampo Hernandez, Antonio / Peres Bares, María Lourdes / López Rojano, Marta / Suy Franch, Anna / Viñuela Beneitez, M Carmen / González Tomé, María Isabel

Enfermedades infecciosas y microbiologia clinica

2014 Volume 32, Issue 5, Page(s) 311–319

Abstract: The main objective in the management of HIV-infected pregnant women is prevention of mother-to-child transmission; therefore, it is essential to provide universal antiretroviral treatment, regardless of CD4 count. All pregnant women must receive adequate ...

Abstract	The main objective in the management of HIV-infected pregnant women is prevention of mother-to-child transmission; therefore, it is essential to provide universal antiretroviral treatment, regardless of CD4 count. All pregnant women must receive adequate information and undergo HIV serology testing at the first visit. If the serological status is unknown at the time of delivery, or in the immediate postpartum, HIV serology testing has to be performed as soon as possible. In this document, recommendations are made regarding the health of the mother and from the perspective of minimizing mother-to-child transmission.
MeSH term(s)	Female ; HIV Infections/prevention & control ; HIV Infections/transmission ; Humans ; Infant, Newborn ; Infectious Disease Transmission, Vertical/prevention & control ; Pregnancy ; Pregnancy Complications, Infectious/prevention & control
Language	English
Publishing date	2014-05
Publishing country	Spain
Document type	Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1070941-1
ISSN	1578-1852 ; 0213-005X
ISSN (online)	1578-1852
ISSN	0213-005X
DOI	10.1016/j.eimc.2013.12.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

Kategorien

Inter-library loan at ZB MED

Full text online

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito